Elotuzumab for the treatment of multiple myeloma

Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yucai, Sanchez, Larysa, Siegel, David S., Wang, Michael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946088/
https://www.ncbi.nlm.nih.gov/pubmed/27417553
http://dx.doi.org/10.1186/s13045-016-0284-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946088/
https://www.ncbi.nlm.nih.gov/pubmed/27417553
http://dx.doi.org/10.1186/s13045-016-0284-z

Ejemplares similares